Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function

Summary: Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 d...

Full description

Bibliographic Details
Main Authors: Dana Al Rijjal, Ying Liu, Mi Lai, Youchen Song, Zahra Danaei, Anne Wu, Haneesha Mohan, Li Wei, Francisco J. Schopfer, Feihan F. Dai, Michael B. Wheeler
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221008774